Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCB84 in advanced solid tumors
NCT05941507Phase 2Recruiting
- Sponsor
- LigaChem Biosciences
- Start
- Oct 2023
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of LCB84 in solid tumor (advanced stage), sponsored by LigaChem Biosciences. Started Oct 2023; status: recruiting.
02
Drugs
LCB84
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05941507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941507.